Immunotherapy Foundation (IF) is dedicated to eradicating HPV-related cancers by catalyzing immunotherapy research and advancing the HPV vaccine as a critical cancer prevention tool. From inception, IF has strategically supported the most promising cancer immunotherapy research for HPV-driven cancers, working directly with world-class researchers to accelerate the discovery and development of new immunotherapies. All projects are designed to bring promising human therapies to the clinic within 18 months of funding. The projects are tightly interconnected to leverage information, holding promise to extend to other malignancies. In 2017, to comprehensively address the HPV-related cancer burden, IF expanded its scope to include educational programming and advocacy for the HPV vaccine.